PHOENIX — A single injection of sura-vec reduced the severity of nonproliferative diabetic retinopathy for up to 2 years, according to data presented at Optometry’s Meeting.
“Early intervention is essential to prevent progression to blinding complications, yet the burden of frequent intravitreal injections with current anti-VEGF therapies make long-term treatment difficult for many patients,” Steve Pakola, MD, chief medical officer at Regenxbio, told Healio. “We believe sura-vec has the potential to redefine the treatment paradigm by delivering sustained anti-VEGF expression through a
— Curated from external eye-care sources for opthametry.com readers.
📰 Original Source: Healio Optometry
Discover more from An Eye Care Blog
Subscribe to get the latest posts sent to your email.
